UK markets close in 7 hours 45 minutes
  • FTSE 100

    +0.31 (+0.00%)
  • FTSE 250

    -176.59 (-0.86%)
  • AIM

    -3.20 (-0.36%)

    -0.0014 (-0.12%)

    -0.0033 (-0.27%)

    -424.95 (-2.17%)
  • CMC Crypto 200

    -10.98 (-2.01%)
  • S&P 500

    +60.55 (+1.47%)
  • DOW

    -39.02 (-0.11%)

    -0.30 (-0.40%)

    -2.70 (-0.14%)
  • NIKKEI 225

    +107.41 (+0.39%)

    -297.89 (-1.36%)
  • DAX

    -152.57 (-0.98%)
  • CAC 40

    -51.04 (-0.71%)

The Worldwide Human Rabies Vaccines Industry is Expected to Reach $932.4 Million by 2027 at a 6.23% CAGR

Company Logo
Company Logo

Global Human Rabies Vaccines Market

Global Human Rabies Vaccines Market
Global Human Rabies Vaccines Market

Dublin, Dec. 28, 2022 (GLOBE NEWSWIRE) -- The "Global Human Rabies Vaccines Market (2022-2027) by Cell Line Type, Route of Administration, Applications, Distribution Channel, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis" report has been added to's offering.

The Global Human Rabies Vaccines Market is estimated to be worth USD 689.3 million in 2022, and is expected to reach USD 932.49 million by 2027, growing at a CAGR of 6.23%.

Report Attribute


No. of Pages


Forecast Period

2022 - 2027

Estimated Market Value (USD) in 2022

$689.3 Million

Forecasted Market Value (USD) by 2027

$932.49 Million

Compound Annual Growth Rate


Regions Covered


Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors.

There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

The Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Human Rabies Vaccines Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

  • The Global Human Rabies Vaccines Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

  • Based on the SWOT analysis conducted on the industry and industry players, suitable strategies have been devised for market growth.

Why Buy This Report?

  • The report offers a comprehensive evaluation of the Global Human Rabies Vaccines Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.

  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.

  • The report also includes the regulatory scenario within the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.

  • The report also contains competitive analysis using 'Positioning Quadrants'; a proprietary competitive positioning tool.

Market Dynamics


  • Increasing Prevalence of Mortality Due to Rabies

  • Rise in the Number of Pets and Stray Dogs

  • Lack of Management Services and Low Rate of Immunization in Pets


  • Common Side Effects Caused by the Vaccines

  • Improper Vaccine Supply in Remote Areas


  • Proliferation in Research and Development Activities

  • Increase in the Production of Vaccine


  • Reduced Awareness and Government Initiatives

  • Strict Regulations Pertinent to Efficacy and Safety

Market Segmentation

The Global Human Rabies Vaccines Market is segmented based on Cell Line Type, Route of Administration, Applications, Distribution Channel, and Geography.

  • By Cell Line Type, the market is classified into BHK cells, Chick Embryo Cells, and Vero Cell.

  • By Route of Administration, the market is classified into Intravenous and Subcutaneous.

  • By Applications, the market is classified into Post Exposure Prophylaxis, and Pre Exposure Prophylaxis.

  • By Distribution Channel, the market is classified into Hospital Pharmacy, and Retail Pharmacy.

  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Companies Mentioned

  • AstraZeneca

  • Bavarian Nordic

  • Berna Biotech

  • Bharat Biotech

  • Cadila

  • Cipla

  • Cpl Biologicals

  • CSC Pharmaceutical

  • Elanco Animal Health

  • GlaxoSmithKline

  • Indian Immunologicals

  • Liaoning Chengda Biotechnology

  • Medimmune

  • Merck

  • Novartis

  • Pfizer

  • Sanofi

  • Serum Institute of India

  • Virbac

  • Wyeth

  • Yisheng Biopharma

  • Zoetis

  • Zuventus

For more information about this report visit


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900